JOHNSON & JOHNSON — Form 8-K
Filed August 4, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 42/100
What the filing says
Jennifer Taubert, EVP and Worldwide Chairman of Innovative Medicine (which generated >$60B annual revenue), is retiring after 21 years. Tom Cavanaugh, currently Company Group Chairman North America Innovative Medicine, will succeed her effective September 1, 2026, and join the Executive Committee. No severance amounts, equity details, or financial terms disclosed.
Why this rating
Leadership transition in $60B division (16% of company revenue) is meaningful but orderly succession planned. No business disruption flagged; successor is internal promotion with 9-year J&J tenure. Routine executive succession for $367B company.
See more from August 4, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.